Sponsor Overview
Explore verified public information about Otsuka America Pharmaceutical's expanded access programs, compassionate use policies, and patient eligibility pathways. This report aggregates official statements, independent research, and regulatory data to help patients, providers, and sponsors collaborate efficiently.
Unique references curated across 1 content categories.
ClinicalTrials.gov data sources power this status.
Dataset refreshed continuously through Right2Hope ETL pipelines.
Expanded Access Intelligence
Official Statements
Score contribution: 100 — 1 supporting sources.
“For patients who may want to participate in a clinical trial, but may not be able to, there is still a possibility to access an investigational drug through the Expanded Access program. Expanded access, also known as compassionate use, allows for an investigational medical product that has not yet been approved by the FDA to be used outside of a clinical trial. Otsuka accepts requests for expanded access from physicians currently treating patients for whom there are no other treatment options available.”
Reagan-Udall Foundation Insights
Partner with Right2Hope
Right2Hope helps sponsors translate regulatory programs into actionable patient access pathways. Connect with our team to publish new programs, streamline intake workflows, or align with providers seeking compassionate use options.